These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 23528430

  • 1. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, Shah N, Cataldo T, Safran H, Hixson D, Quesenberry P.
    Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M, Carballo M.
    BMC Cancer; 2011 Sep 24; 11():406. PubMed ID: 21943394
    [Abstract] [Full Text] [Related]

  • 3. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, Choppa P, Labourier E.
    J Clin Pathol; 2011 Jan 24; 64(1):30-6. PubMed ID: 21030527
    [Abstract] [Full Text] [Related]

  • 4. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
    Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.
    Mod Pathol; 2011 Aug 24; 24(8):1090-100. PubMed ID: 21516079
    [Abstract] [Full Text] [Related]

  • 5. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
    Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S, Dandachi N, Zeillinger R, Kriegshäuser G.
    J Mol Diagn; 2009 Nov 24; 11(6):508-13. PubMed ID: 19797612
    [Abstract] [Full Text] [Related]

  • 6. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
    De Miglio MR, Mura A, Uras MG, Manca A, Contini M, Murgia L, Zinellu A, Sotgia S, Carru C, Massarelli G, Cossu-Rocca P.
    Diagn Mol Pathol; 2010 Dec 24; 19(4):201-8. PubMed ID: 21052001
    [Abstract] [Full Text] [Related]

  • 7. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
    Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K, Japanese Society of Medical Oncology.
    Cancer Sci; 2015 Mar 24; 106(3):324-7. PubMed ID: 25800101
    [Abstract] [Full Text] [Related]

  • 8. KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.
    Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T.
    Int J Mol Sci; 2011 Mar 24; 12(5):3191-204. PubMed ID: 21686179
    [Abstract] [Full Text] [Related]

  • 9. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A.
    BMC Cancer; 2008 May 21; 8():142. PubMed ID: 18495026
    [Abstract] [Full Text] [Related]

  • 10. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
    Carotenuto P, Roma C, Cozzolino S, Fenizia F, Rachiglio AM, Tatangelo F, Iannaccone A, Baron L, Botti G, Normanno N.
    Int J Oncol; 2012 Feb 21; 40(2):378-84. PubMed ID: 21971641
    [Abstract] [Full Text] [Related]

  • 11. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.
    Nature; 2012 Jun 28; 486(7404):532-6. PubMed ID: 22722830
    [Abstract] [Full Text] [Related]

  • 12. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.
    Br J Cancer; 2009 Aug 18; 101(4):715-21. PubMed ID: 19603018
    [Abstract] [Full Text] [Related]

  • 13. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
    Dono M, Massucco C, Chiara S, Sonaglio C, Mora M, Truini A, Cerruti G, Zoppoli G, Ballestrero A, Truini M, Ferrarini M, Zupo S.
    Mol Med; 2013 Feb 08; 18(1):1519-26. PubMed ID: 23255073
    [Abstract] [Full Text] [Related]

  • 14. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.
    Cytopathology; 2011 Dec 08; 22(6):358-64. PubMed ID: 21029218
    [Abstract] [Full Text] [Related]

  • 15. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I, Cillero L, Sanz-Ortega J, Llovet P, Pescador P, Ferrer M, de la Hoya M, Sastre J, García ED, Caldés T.
    Clin Transl Oncol; 2012 Dec 08; 14(12):937-42. PubMed ID: 22865324
    [Abstract] [Full Text] [Related]

  • 16. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
    Chang YS, Er TK, Lu HC, Yeh KT, Chang JG.
    Clin Chim Acta; 2014 Sep 25; 436():169-75. PubMed ID: 24863805
    [Abstract] [Full Text] [Related]

  • 17. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
    Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J.
    BMC Cancer; 2010 Dec 01; 10():660. PubMed ID: 21122130
    [Abstract] [Full Text] [Related]

  • 18. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
    Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S, Lawrence HJ.
    Virchows Arch; 2012 Feb 01; 460(2):141-9. PubMed ID: 22173329
    [Abstract] [Full Text] [Related]

  • 19. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.
    Ann Oncol; 2012 Jun 01; 23(6):1518-25. PubMed ID: 22039088
    [Abstract] [Full Text] [Related]

  • 20. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
    Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R.
    J Clin Pathol; 2014 Sep 01; 67(9):764-7. PubMed ID: 25004944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.